An assay for thrombin is presented wherein thrombin-catalyzed hydro--lysis at Arg-Au-16 to release fibrinopeptide A (FPA) from fibrinogen is measured using high-performance liquid chromatography (HPLC). In this assay one thrombin unit (TU) is defined as that amount of thrombin that will release half of the FPA in one min from one ml of a solution of >90% clottable normal human fibrinogen (LO.35 u.21) at 37'C, pH 7.4, r/2 0.15. One TU is equivalent to "d 0.1 NIH unit of thrombin and '7, 1 pm01 of pure human thrombin. At 37'C, pH 7.4, and plasma levels of fibrinoqen-yf 3 mq/ml, one TU will catalyze the release of 3.6 nmol FPA min . Variability in fibrinogen samples which produce dramatic differences in clotting time assays with the same sample of thrombin, produce little or no variation in the catalytic assay for TU. The assay for TU obviates the need for maintenance of a thrombin reference standard.
INTRODUCTION
Thrornbin is most frequently assayed from measurements of its effectiveness in clotting fibrinogen.
In this assay, the time from the initiation of the reaction to the formation of a clot is related to the concentration of active thrombin.
Several discussions and descriptions of the clotting time assay have been published (e.g. l-6). Since the clotting time assay uses a natural substrate of thrombin, the assay should yield a reliable measure of the biological activity of a sample of thrombin.
Clotting times, however, are functions of both thrombin-catalyzed proteolytic events and fibrinogen 'Tohom inquiries should be sent. It is therefore not surprising that thrombin clotting times vary with the quality of fibrinogen, the age of fibrinogen solutions, as well as with the presence of inhibitors of fibrin polymerization. This variability has made it necessary to maintain a thrombin reference standard.
The commonly used NIH unit of thrombin is defined as that amount of thrombin which in 15 set will clot 1 ml of fibrinogen that has been standardized with the thrombin reference standard.
Thus, the activity of the thrombin sample is defined in terms of its potency relative to that of the thrombin reference standard rather than in terms of absolute catalytic activity. The need for the reference standard might be obviated by use of a thrombin assay based on direct measurement of its hydrolytic activity.
Assays based on direct measurements of the catalytic activity of thrombin should employ a specific substrate of thrombin (e.g. fibrinogen) to reflect the biological activity of the sample and to minimize the effect of other hydrolases which may be present in the sample of thrombin.
In 1958, Jorpes et al. (3) , proposed standardization of thrombin from measurements (at pH 9.0-&d GC) of the appearance of N-terminal glycine, which occurs upon thrombincatalyzed cleavage at the peptide bond between Arg-Aal and Gly-Aal in fibrinogen.
The feasibility of this thrombin determination was demonstrated by Magnusson (4) in 1960. The assay which involves Edman degradation of the thrombin treated fibrinogen followed by separation and quantification of PTH-derivatives has not gained general acceptance.
With the advent of HPLC and immune assays for FPA, however, it has become more facile to monitor the thrombin mediated proteolysis at Arg-AcilG. We present here an assay for thrombin which is based on measurements (using HPLC) of the rate of release of FPA which occurs in the thrombin catalyzed cleavage of fibrinogen at Arg-Acrl6. The assay obviates the need for a thrombin reference standard and yields a direct estimate of the proteolytic activity of thrombin at pH 7.4, 37'C, and r/2 = 0.15.
METHODS
Fibrinogen -The laboratory prepared fibrinogen (L) was purified from outdated plasma by the method of Jakobsen and Kierulf (7), except that the fibrinogen solvent used to redissolve fibrinogen was the citrate saline solvent of Straughn and Wagner (8) , and final dialysis was against 0.30 M NaCl. This fibrinogen preparation behaved identically to the fibrinogen preparation used previously in this laboratory (9). Other fibrinogen samples used were from commercial sources.
Their source and designation (in parenthesis) in this paper are: Sigma #F-3879, Lot #81F-9365, (S-I); Sigma #F-4129, Lot #51F-9300 (S-II); Calbiochem #341576, Lot #201561 (C); Kabi, Grade L, Lot #30853 (K) and Cutter, PurengenH, Code 611-68 (Cu). Weighed amounts of these powders were dissolved in 0.30 M NaCl, dialyzed, centrifuged and used.
IMCO fibrinogen (I) in 50 mM Tris-HCl, 0.10 M NaCl, pH 7.5 was a generous gift from L. Lorand of the Department of Biology and Molecular and Cell Biology, Northwestern University, Evanston, Illinois, 60201.
It was dialyzed into 0.30 M NaCl before use. All fibrinogen solutions were stored at -70°C prior to use.
Thrombin -Thrombin reference standard (Lot J) was provided by the Bureau of Biologics, Bethesda, MD, and contained 310 NIH units per ampule.
Heconstitution was achieved either by addition of 1 ml of 0.01 M phosphate buffer, 0.14 M NaCl, pH 7.4, containing 0.5% PEG or by addition of 1 ml of standard assay buffer (see below).
John W. Fenton II, New York State Department of Health, generously provided the purified human thrombin (2.87 NIH units/ug) used in this work.
The thrombin which was greater than 93% active by active site titration (10) was stored in 0.3 M NaCl at -7O'C. a-Thrombin accounted for >99% of the thrombin in both samples. The concentration of thrombin was 1% determined from its absorbance at 280 nm using an ET,9 of 18.3 in 0.1 ?I NaOH L ., and an Xr of 36,500 (11).
Clottinq times -Clotting times were determined essentially as described by D.J. Baughman (S), wherein 0.2 ml of 1.58 mg/ml (clottable protein) was rapidly mixed with 0.1 ml of 3 NIH units/ml thrombin in a buffer system of 0.05 M phosphate, r/2 = 0.15, pH 7.0, 25'C giving a final concentration of 1.05 mg/ml clottable protein and 1 NIH unit/ml of thrombin.
Clottable fibrinogen was determined by the method of Baughman (5). An E:Ll of 15.1 and a molecular weight of 340,000 was used to calculate fibrinogen concentrations.
Reaction kinetics -The release of FPA was measured at pH 7.4, 37"C, in phosphate buffered solutions as specified in the text.
In the recommended standard assay for release of fibrinopeptides, 1 ml of 3.5 yM fibrinogen (7 PM Au-chains, 1.2 mg/ml) in 0.3 M NaCl was added to 10 ml of assay buffer.
(The assay buffer was prepared by addition of a solution consisting of 0.05 M M2POl+, 0.1 b,j NaCl and 0.1% PEG 6000 to a solution consisting of 0.05 M Na2HP04 and 0.1% PEG 6000 until pH 7.40 was obtained.) A 0.9 ml aliquot of the fibrinogen-containing assay buffer was transferred to a microfuge tube for determination (see below) of the peak area or height corresponding to FPA at zero time, (RFPA),. Six ml of the remaining solution was then equilibrated at 37'C, and mixed with lo-200 ul of an appropriate dilution of thrombin solution. Care was taken to dilute the thrombin stock solution with assay buffer containing PEG 6000 to prevent adsorption of thrombin on surfaces (12). Wit!?-in 2 min of the addition of thrombin, before formation of a visible clot, 0.9 ml aliquots of the reaction mixture were added to six microfuge tubes which had been equilibrated at 37OC. To one tube, excess thrombin (e.g. 10 vl of 3-5 NIH units/ml) was added for determination at the end of 30 min of the peak area or height corresponding to total releasable FPA, (RFPA)f. The remaining 5 tubes were incubated at 3J°C, and quenched after the desired incubation times by addition of 0.1 ml of 3 M HC104.
After addition of the 3 M HClOl+, which was also added to the zero-time and excess thrombin samples, water was added so that the total volume of liquid added to each sample was 1.3 ml. After 10 min the precipitated protein was rerroved by centrifugation, and 1 ml of the resulting supernatant solution was injected into the HPLC system for determination of the area or height of the FPA peak. An automatic sample injector (Wisp from Waters Associates) was used to facilitate handling of multiple samples.
If sufficient points were not obtained at C>-0.25 (see text) for a precise determination of TU/ml, additional values of !! were determined with the remaining fibrinogen solution, using either other incubation times or another dilution of thrombin.
The standard assay for TU/ml (see text) is independent of the absolute value of quenched assay solution injected into the HPLC system, provided that each determination of A is obtained from measurements of RFPA, (RFPA), and (RFPA)f which are based upon the same amount of fibrinogen.
HPLC -A Varian 5000 liquid chromatograph was used for HPLC.
The peptides were detected at 205 nm using a model 450 variable wave length detector from Waters Associates.
Fibrinopeptide separation upon the 1 ml injection was achieved using a Waltman Particil-lo-ODS-3 (0.46 x 25 cm), Ultrasphere OPS 511 (0.46 x 25 cm) or Spherisorb ODS-2 3u (0.46 x 10 cm) column, all equipped with a Waltman pre-column (0.21 x 5 cm). Various two-buffer gradient systems were studied for their effectiveness in peptide elution.
The buffer systems were: from reference 6 where Buffer A is 0. The sodium phosphate system employe ?l (pH 2.0) and for the standard assay used a linear gradient system which went from ~O%A, 30%B to lO%A, 90%B in 40 min at flow rate of 1 ml/mn.
The area under the FPA peak was proportional to the amount of FPA. Under conditions where sharp peaks were obtained (e.g., with the Spherisorb, ODS-2 3~ column) the peak height was also proportional to the amount of FPA.
RESULTS
Several systems have been reported recently for the quantification of the release of fibrinopeptides from fibrinogen using reverse phase HPLC chromatography (e.g. 9,13,14).
These systems which differ with respect to the column used and the composition of the aqueous component of the eluent buffer, were evaluated for their suitability for use in a thrombin assay.
The composition of eluent buffer was found to be an important determinant of peptide recovery.
The phosphate buffer system described here reproducibly yielded the highest recovery of FPA (>90%). i; cm-lYy-l (FDA) and 5.12 x lo4 cm-IM-l (FP3).
The thrombir-catalyzed release of FPA from fibrinogen has also been shown (15) to follow simple Michaelis-Menten kinetics.
At pH 7.4, 37'=C, r/2 = 0.15, Km for the release of FPA is 7.2 I.M based on the concentration of Aachains.
When the concentration of Au-chains is less than 0. 
Integration of equation 2 yields 
where RFPA is the area or height of the FPA peak and the subscripts o, and f denote values before the addition of thrombin and after sufficient incubation with thrombin so as to release all of the FPA. Peak height rather than area could be used for RE'PA when the chromatogram yielded sharp peaks whose height was proportional to the amount of FPA.
A time dependence for the release of FPA is shown in Fig 2A for Since l/toes is proportional to the thrombin concentration, it may be used to specify thrombin content. If a thrombin unit (TU) is defined as that amount of human thrombin which will release half the FPA in one min from 1 ml of 90% clottable human fibrinogen (50.35 JIMI at 37'C, pH 7.4, r/2 = 0.15; l/to S is equivalent to the concentration of thrombin units (TU/ml) in the assay mixture.
Inspection of equatioml-5 reveals that thrombin units can be determined from measurements of peak areas or height without knowledge of the absolute concentration of functional fibrinogen as long as the fibrinogen concentration is SO.35 u# (i.e. LO.70 PM Aa-chains).
The :e close to 0.5) using a fibrinogen solution with a previously determined v;al~;e __ of (RFPAJo and (P.FPA\)f. Precise values of TU, however, are best determined using more than one value of i?. It is also important to periodically reevaiuate (RFPAjo and (PFPA)f, since variations in flow rate, injection volume and fibrinogen concentration in the sample will cause the absolute values of (RFPA),, (RFPA)f and (RFPA) to change. The solid lines were calculated using equation 3 and a value of for kcat [Throml/Km which gave the best fit of the data to equation 3.
TIME (MINI
Thrombin units may also be estimated from equation 6. TU/ml = l/to.5
Values of TU obtained by averaging several values of TU, estimated from measurements of A at times 5 2t0 5, should yield the most reliable estimates of TU. Values of A at t > 2t0 5'should be avoided, however, since small errors in the determination of P,FPA for these points can result in large relative errors in TU.
The data in Table I illustrate that the determination of TU is essentially independent of the fibrinogen sample used.
Seven different samples of fibrinogen with clottabilities ranging from 79% -96% exhibited 0.21 ? 0.01 TU when assayed with 0.02 NIH unit of thrombin having a specific activity of 2.87 NIH unitlug.
The variation between the highest and lowest determination of TU was 17%, whereas the corresponding variation for thrombin clotting times (determined with 1 NIH unit/ml of thrombin) was 140%.
Under the conditions used for the assay, the release of FPA is followed by end to end polymerization which in turn is followed by the release of FPB (15). It is therefore not surprising that the release of FPA is not affected aTU/ml was evaluated with 0.32 uM fibrinogen in 10 m&l phosphate which was mixed under the assay conditions with 0.02 NIH unit of thrombin/ml. Clotting times were determined at 1 NIH unit/ml of thrombin.
by the presence of polymerization inhibitors such as Gly-Pro-Arg-Pro and EDTA (Fig 3) . These inhibitors, however, drastically prolong the clotting times and inhibit the release of FPB (15). In addition to being insensitive to the presence of polymerization inhibitors the determination of thrombin units was unaffected by the presence of 1mM Ca+2.
The assays described up to this point in the text were carried out in the presence of a low concentration of phosphate buffer (10 mM) to approximate plasma concentrations of phosphate and TIME (MIN) Of no additions; izl, 0.54 mM Gly-Pro-Arg-Pro; minimize precipitation which occurs when Ca+2 is added to a more concentrated phosphate buffer.
To minimize the possibility of inadvertent alterations in pH a more concentrated phosphate buffer (0.05 M) is suggested for the standard assay. Fig 4 illustrates The estimate that 3.09 I c.56 ?:IH unit (11) is equivalent to 1 "g of pure human thrombin together with the observatioz that 1 TJ is equivalent to 0.118 NIH unit indicates that 1 TU is equi,ialent to 1.05 t 0.19 pm01 of pure human tnrombin (ML. = 36,500).

FIG. 4
Relationship between thrombin-units and NIH units.
The recommended standard assay described under "Methods" was used wherein 10 ~1 co), 25 ul (m), 50 ~1 (A) and 100 ~1 (0) of a stock solution of thrombin NIH reference standard containing 2.55 NIH units/ml was added to 6 ml aliquots of 0.32 uM fibrinogen in assay buffer to yield 0.00424, 0.0106, 0.0211, 0.0418 NIH unit/ml thrombin. The values of TU/ml (l/tO.5) determined from plots in Fig 4A are plotted in Fig  4B against the corresponding values of NIH/ml in the assay buffer.
THROMBIN (NIH U/ML)
DISCUSSION
The standard assay for thrombin units described under "Methods" is based upon the proteolytic activity of thrombin toward one of its natural substrates under conditions of pH, temperature, and ionic strength close to those used in many biological applications of thrombin.
The assay which is based upon thrombin catalyzed release of FPA is insensitive to the presence of polymerization inhibitors.
It should also be unaffected by variations in fibrinogen structure spatially remote from the scissile bond.
Winen normal human fibrinogen with a clottability ? 90% is used, no significant dependence of the assay on the fibrinogen is detected.
Thus, the assay does not require a thrombin reference standard for calibration.
Another advantage of the assay is that the thrombi unit specifies the catalytic potency of thrombin samples in molecular terms- which predicts the rate of release of FPA in pM-min -1 as a function of the u molar concentration of Act-chains o f fibrinogen and the concentration of thrombin. At a plasma concentration of fibrinogen of 3 mg/ml (17.6 T.IM AZ-chains), one TU shoilld catalyze the release of 3.6 nmol FPA/min at 37'C, pH 7.4.
The assay presented here differs from most determinations of enzyme activity in that it relies on the determination o f half--lives for the first-order decay of substrate rather than the determination of initial velocities for substrate decomposition.
Reproducible determination of initial velocities usually requires duplication of functional substrate concentrations. This could be problematical when different samples of fibrinogen are used.
Halflives for the first order release of FPA, however, should be independent of the initial substrate concentration, as long as [Aa] 2 O.l*Km.
It is realized that the dependence of an initial velocity assay on variations in substrate concentration could be reduced by use of an initial substrate concentration which is substantially greater than Km. It was not considered advisable, however, to design an assay with a high fibrinogen concentration, since the presence of compet itive inhibitors (e.g. fibrinogen degradation products) which might be associated with certain fibrinogen samples could result in variations in initial velocity.
That is, at a near saturating substrate concentration only a small fraction of the thrombin will be free, and the thrombin will be distributed between substrate and inhibitor according to their relative concentration and affinity for thrombin.
At the low concentrations of fibrinogen specified for the assay presented in this work, less than 10% @f the thrombin is Saturated by fibrinogen.
Under such conditions, contaminating competitive inhibitors are not likely to result in displacement of fibrinogen from thrombin.
It is important to note that in some chromatographic systems the phosphorylated FPA is not resolved from FPA. The time dependence of the release of these two peptides do not differ significantly at the low fibrinogen concentration used for the assay.
Thus, thrombin units can be accurately determined from measurements of the areas or heights of peaks resulting from the combined presence of both peptides.
It is conceivable that certain laboratories will find it more convenient to continue to determine thrombin units from clotting times using a thrombin reference standard.
The methods presented here, however, should also facilitate this approach by providing the means for direct measurement of the catalytic potency of the thronibin standard needed to calibrate the fibrinogen. Additionally, the observation that there are 8.5 TU/NIH unit establishes a relationship between the proteolytic activity and the clotting-time assay for human thrombin.
